GlassScriptPhysician profile
Amy M Traylor
NPI 1972000149
$1,102.39
in general payments reported to CMS, 2019-2025
15 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.30 · 2022: $44.57 · 2023: $151 · 2024: $395 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.15 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $139.34 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $92.52 | 2024-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $90.70 | 2023-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $88.58 | 2023-2025 | Wegovy, Ozempic |
| Supernus Pharmaceuticals, INC. | $49.24 | 2024-2025 | Qelbree |
| Pfizer INC. | $47.87 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.83 | 2025 | Caplyta |
| Exact Sciences Corporation | $45.77 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $24.48 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $23.96 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $18.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.97 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $13.87 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Traylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.